Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26798599 | 0.89 | LMNA (0.54) | MAOBLMNACYP1A2CYP3A4MAOA | |
| SCHEMBL10465995 | 0.87 | MAOB (0.65) | MAOBLMNAPDGFRBPDGFRAHPGDS | |
| SCHEMBL8001650 | 0.86 | MAOB (0.71) | MAOBPDGFRBPDGFRAHPGDSNPC1 | |
| SCHEMBL2202317 | 0.84 | MAOB (0.66) | MAOBLMNAPDGFRBPDGFRAHPGDS | |
| SCHEMBL3575601 | 0.84 | HPGDS (0.54) | MAOBHPGDSRAB9ASMN1; SMN2MAPT | |
| SCHEMBL17447286 | 0.83 | MAOB (0.61) | MAOBLMNAPDGFRBPDGFRAHPGDS | |
| SCHEMBL4538765 | 0.83 | MAOB (0.61) | MAOBPDGFRBPDGFRAHPGDSNPC1 | |
| SCHEMBL4156881 | 0.83 | MAOB (0.61) | MAOBLMNAPDGFRBPDGFRAHPGDS | |
| SCHEMBL2204650 | 0.83 | MAOB (0.65) | MAOBCYP1A2PDGFRBPDGFRAHPGDS | |
| Hydrochloric Acid SCHEMBL1353034 | 0.83 | HPGDS (0.52) | MAOBHPGDSRAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | claimed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | claimed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-20230348394-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-20230348394-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1157695-B1 | Method of treating obesity using a neurotensin receptor ligand | PFIZER PROD INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1585751-A | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-23 | — | — | CN | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-6734175-B2 | ADMINISTERING TO AN OBESE PATIENT OR ONE AT RISK OF BECOMING OBESE A THERAPEUTIC COMPOUND THAT ATTENUATES THE BINDING OF AGOUTI-RELATED PROTEIN TO MELANOCORTIN RECEPTORS, FREE OF BINDING OF ALPHA-MELANOCYTE STIMULATING HORMONE TO RECEPTOR | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| US-20020065277-A1 | Treatments for obesity and methods for identifiying compounds useful for treating obesity | HADCOCK JOHN R (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020042516-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-04-11 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010046956-A1 | Methods of treating obesity using a neurotensin receptor ligand | HADCOCK JOHN R (US) | 2001-11-29 | — | — | US | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125579-A2 | Uses of agrp-melanocortin receptor binding modulating compounds | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042516-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | MAOB 509/4885LMNA 1997/4885CYP1A2 86/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | MAOB 130/4885LMNA 2331/4885CYP1A2 409/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | MAOB 2222/4885LMNA 3725/4885CYP1A2 209/4885 |
| US-20230348394-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES | TNNC1, PYGM, GYS1 | MAOB 2953/4885LMNA 75/4885CYP1A2 4872/4885 |
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | MAOB 58/4885LMNA 3399/4885CYP1A2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.